Leveraging Technology to Cut Through the REMS Confusion
The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.
You may also like:
According to a recent Centers for Disease Control (CDC) report, 63% of accidental deaths in the U.S. are attributed to some form of opioid use or misuse. Mounting concern over the national crisis of opioid abuse and overutilizatio...
Two recent studies took a closer look at the question of whether antibiotics prevent postoperative complications after third molar surgery. Both found that there are fewer postoperative complications after using antibiotics.
Heads up! Risk Evaluation and Mitigation Strategies, or REMS, have been referenced in a number of recent industry discussions and could present significant challenges to the practice and business of pharmacy over the next several ...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!